📅 Published March 30, 2026 | ♻️ Reviewed August 2, 2026 | 🏷 IVF
PGT-A: Evidence, Limits and Individualized IVF Decisions
Summary:PGT-A assesses embryos for aneuploidy, but it is not a routine requirement for every IVF patient and cannot guarantee a healthy embryo, pregnancy or live birth. Its value must be evaluated by separating outcomes per embryo transfer from cumulative live birth per egg retrieval, then considering age, blastocyst number, prior history, laboratory performance and patient preferences.
What is PGT-A?
PGT-A stands for preimplantation genetic testing for aneuploidy. A laboratory usually biopsies several trophectoderm cells from a blastocyst and reports the sample as euploid, aneuploid, mosaic or inconclusive.
The result describes the sampled cells. It is not an absolute diagnosis of the whole embryo, does not certify that an embryo is “healthy,” and does not replace PGT-M, PGT-SR, prenatal screening or prenatal diagnosis.
ASRM 2024 conclusion:The value of PGT-A as a routine screening test for all IVF patients has not been demonstrated. Use should be discussed case by case with the treating reproductive physician and, where appropriate, a genetics professional.
Two outcome denominators must not be mixed
Outcome
Denominator
How to interpret PGT-A data
Outcome per transfer
Embryos or cycles that reached transfer
The population entering transfer has already been selected, so per-transfer results may look better in some groups. This does not establish benefit for the whole retrieval cycle.
Cumulative live birth per retrieval
All embryos and transfers arising from one egg retrieval
PGT-A does not create embryos. Some embryos may not proceed to transfer because of aneuploid, mosaic or inconclusive results, so the cumulative outcome can differ.
Quoting the performance of transfers using embryos reported as euploid as proof that PGT-A improves overall IVF success mixes denominators. Ask a clinic for age-stratified per-transfer outcomes, cumulative live birth per retrieval, inconclusive-result rates and the proportion of retrievals with no embryo available for transfer.
Process and limitations
Blastocyst development:Embryos are cultured to a stage suitable for biopsy.
Trophectoderm biopsy:A small sample is taken from cells that mainly contribute to the placenta.
Freezing and analysis:The embryo is usually frozen while the sample undergoes chromosome analysis.
Interpretation:The physician and genetics team consider euploid, aneuploid, mosaic or inconclusive reports when planning next steps.
Biopsy is not risk-free:Sampling representation, mosaicism, laboratory procedures and reporting criteria can affect interpretation. Biopsy, freezing and warming also carry technical limitations. Absolute claims that biopsy cannot affect an embryo or that testing necessarily improves success are not supported.
When is an individualized discussion useful?
Age, expected blastocyst number and the likelihood of obtaining an embryo reported as euploid.
Prior pregnancy losses, failed transfers and complete embryology records; these histories do not automatically make PGT-A necessary.
Whether a structural chromosome rearrangement calls for PGT-SR or a monogenic condition calls for PGT-M.
When only a small number of blastocysts is expected, whether the information gained justifies cost, delay and the possibility that no embryo proceeds to transfer.
The laboratory’s biopsy experience, inconclusive-result rate, mosaic-embryo policy and warming outcomes.
Questions to answer before treatment
Define the goal:Is the aim to reduce transfers, obtain genetic information, or improve cumulative live birth per retrieval?
Request like-for-like data:Results should state age, denominator, sample size and reporting period.
Plan for uncertainty:Ask how inconclusive or mosaic results and possible re-biopsy are handled.
Discuss alternatives:These may include transfer without PGT-A, elective single-embryo transfer, PGT-M or PGT-SR when indicated.
Complete informed consent:Consider expected benefit, limitations, cost and personal priorities together.
Summary: PGT-A is a testing tool, not a success-rate promise
PGT-A may help some families prioritize embryos or avoid selected transfers, but its value depends on the patient group and outcome denominator. It cannot create more embryos, and per-transfer results cannot be substituted for cumulative live birth per retrieval. The final plan should be individualized using complete medical and embryology records.
📌 Need to know more about PGT-A or other IVF technologies?